concept

DONANEMAB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DONANEMAB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

87Connections

0Hypotheses

1Analyses

27Outgoing

20Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	DONANEMAB
Summary	Phase 3 trial evaluating different donanemab dosing regimens to reduce ARIA-E incidence - TRAILBLAZER-ALZ 6 study
Key Genes/Proteins	AMYLOID, TAU, APOE
Related Diseases	AUTOPHAGY, AMYLOID PLAQUES

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    DONANEMAB["DONANEMAB"]
    DONANEMAB -->|"treats"| Cognitive_Decline["Cognitive Decline"]
    DONANEMAB -->|"targets"| Amyloid_Beta["Amyloid Beta"]
    DONANEMAB -->|"targets"| Amyloid__["Amyloid-beta"]
    DONANEMAB -->|"binds_to"| amyloid__["amyloid-beta"]
    DONANEMAB -->|"treats"| Alzheimer_s_disease["Alzheimer's disease"]
    DONANEMAB -->|"targets"| AMYLOID_BETA["AMYLOID-BETA"]
    DONANEMAB -->|"treats"| Early_Stage_Alzheimer_s_Diseas["Early-Stage Alzheimer's Disease"]
    ADUCANUMAB["ADUCANUMAB"] -->|"target for"| DONANEMAB
    AMYLOID["AMYLOID"] -->|"implicated in"| DONANEMAB

Outgoing (65)

Target	Relation	Type	Str
LECANEMAB	therapeutic_target	drug	0.80
AUTOPHAGY	activates	phenotype	0.70
AUTOPHAGY	regulates	phenotype	0.70
AMYLOID	targets	protein	0.65
AMYLOID	interacts_with	protein	0.65
AMYLOID PLAQUES	protects_against	phenotype	0.65
AMYLOID	causes	protein	0.65
ADUCANUMAB	treats	drug	0.65
ADUCANUMAB	causes	drug	0.65
AMYLOID	activates	protein	0.65
AMYLOID	treats	protein	0.65
TAU	activates	protein	0.65
AUTOPHAGY	synergizes_with	phenotype	0.60
APOE	associated_with	gene	0.50
AUTOPHAGY	associated_with	phenotype	0.50
ASTROCYTE	associated_with	cell_type	0.50
MICROGLIA	associated_with	cell_type	0.50
APP	associated_with	gene	0.50
AMYLOID	associated_with	protein	0.45
ALZHEIMER	associated_with	disease	0.45
DEMENTIA	associated_with	disease	0.45
LECANEMAB	associated_with	drug	0.45
MMSE	associated_with	biomarker	0.45
CSF	associated_with	phenotype	0.45
TAU	associated_with	protein	0.45
LECANEMAB	implicated_in	drug	0.35
ad_clinical_trial_failures:donanemab	data_in	dataset_row	0.00

Incoming (22)

Source	Relation	Type	Str
ADUCANUMAB	therapeutic_target	drug	0.50
NEUROINFLAMMATION	associated_with	phenotype	0.50
INFLAMMATION	associated_with	phenotype	0.50
ADUCANUMAB	associated_with	drug	0.45
LECANEMAB	associated_with	drug	0.45
COGNITIVE DECLINE	associated_with	phenotype	0.45
AMYLOID	associated_with	protein	0.45
ALZHEIMER	associated_with	disease	0.45
DEMENTIA	associated_with	disease	0.45
AMYLOID PLAQUES	associated_with	phenotype	0.45
AMYLOID-BETA	associated_with	protein	0.45
GANTENERUMAB	associated_with	drug	0.45
SOLANEZUMAB	associated_with	drug	0.45
CRENEZUMAB	associated_with	drug	0.45
RIVASTIGMINE	associated_with	drug	0.45
DONEPEZIL	associated_with	drug	0.45
AMYLOID	implicated_in	protein	0.35
ALZHEIMER'S DISEASE	associated_with	disease	0.35
AMYLOID	therapeutic_target	protein	0.35
ad_clinical_trial_failures:donanemab	data_in	dataset_row	0.00

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.566

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

DONANEMAB

Understanding Entity Pages

Wiki Pages (21)

Donanemab Dosing Regimens Phase 3 for Early Alzheimer's (NCT05738486)

nhp-validation-animal-model

Therapeutics

Alzheimer's Disease

p-tau-217

APOC4 — Apolipoprotein C-IV

University of Heidelberg

dimethyl-fumarate-nrf2-ad-nct06850597

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

PMN310 Anti-Amyloid for AD (NCT06750432)

Clinical Trials Dashboard

Amyloid Cascade Pathway

Cerebrospinal Fluid (CSF) Biomarkers Overview

rankings

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

Gene-Mechanism-Therapy Causal Chains

KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)

Beta-Secretase (BACE1) Protein

uni-pittsburgh

Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)